Detalles de la búsqueda
1.
Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.
Prostate;
84(8): 747-755, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38544345
2.
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study.
Med J Aust;
220(2): 80-90, 2024 02 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38212673
3.
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.
Br J Cancer;
129(5): 797-810, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37474720
4.
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.
BMC Med;
20(1): 112, 2022 03 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35331214
5.
MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG).
BMC Cancer;
21(1): 932, 2021 Aug 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34407800
6.
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Lancet Oncol;
21(9): 1213-1223, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32888453
7.
A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer.
Int J Cancer;
141(10): 2112-2120, 2017 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28741687
8.
Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer.
Br J Cancer;
116(8): 1002-1011, 2017 Apr 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28278515
9.
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
J Clin Oncol;
41(23): 3917-3929, 2023 08 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37307514
10.
Immunotherapy-related gastritis: Two case reports and literature review.
Clin Med Insights Oncol;
15: 11795549211028570, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34290539
11.
Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer.
Cancers (Basel);
13(19)2021 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34638448
12.
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase.
EBioMedicine;
72: 103625, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34656931
13.
Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).
BMJ Open;
8(9): e020745, 2018 09 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30209152
14.
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.
JAMA Oncol;
3(11): 1511-1519, 2017 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28662232
15.
Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma.
J Immunother;
39(3): 149-52, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26938948
16.
Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile?
Eur J Cancer;
46(10): 1800-7, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20137908
Resultados
1 -
16
de 16
1
Próxima >
>>